Metastatic Urothelial Cancer Active Not Recruiting Phase 2 Trials for Nivolumab (DB09035)

Back to Metastatic Urothelial Cancer
IndicationStatusPhase
DBCOND0066157 (Metastatic Urothelial Cancer)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03451331Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial CancerTreatment